Kathleen M. Fairfield

Kathleen M. Fairfield

Auto-generated profile, based on publicly available information

Kathleen M. Fairfield

Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, Maine

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2020 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
KFKathleen M Fairfield
Kathleen M Fairfield
ABAdam W Black
Adam W Black
EZErika C Ziller
Erika C Ziller
KMKimberly Murray
Kimberly Murray
FLF Lee Lucas
F Lee Lucas
PHPaul K J Han
Paul K J Han
Background: We sought to describe lung cancer prevalence and mortality in relation to socioeconomic deprivation and rurality. Methods: We conducted a population-based cross-sectional analysis of prevalent lung cancers from a statewide all-payer claims dataset from 2012 to 2016, lung cancer deaths in Maine from the state death registry from 2012 to 2016, rurality, and area deprivation index (ADI), a geographic area-based measure of socioeconomic deprivation. Analyses examined rate ratios for lung cancer prevalence and mortality according to rurality (small and isolated rural, large rural, or urban) and ADI (quintiles, with highest reflecting the most deprivation) and after adjusting for age, sex, and area-level smoking rates as determined by the Behavioral Risk Factor Surveillance System. Results: Among 1 223 006 adults aged 20 years and older during the 5-year observation period, 8297 received lung cancer care, and 4616 died. Lung cancer prevalence and mortality were positively associated with increasing rurality, but these associations did not persist after adjusting for age, sex, and smoking rates. Lung cancer prevalence and mortality were positively associated with increasing ADI in models adjusted for age, sex, and smoking rates (prevalence rate ratio for ADI quintile 5 compared with quintile 1 = 1.41, 95% confidence interval [CI] =1.30 to 1.54) and mortality rate ratio = 1.59, 95% CI = 1.41 to 1.79). Conclusion: Socioeconomic deprivation, but not rurality, was associated with higher lung cancer prevalence and mortality. Interventions should target populations with socioeconomic deprivation, rather than rurality per se, and aim to reduce lung cancer risk via tobacco treatment and control interventions and to improve patient access to lung cancer prevention, screening, and treatment services.

1 April 2012 in Gynecologic Oncology
Verified
Journal Article
Closed access
KFKathleen M. Fairfield
Kathleen M. Fairfield
KMKimberly M. Murray
Kimberly M. Murray
HWHeidi R. Wierman
Heidi R. Wierman
PHPaul K.J. Han
Paul K.J. Han
SHSarah Hallen
Sarah Hallen
CECraig C. Earle
Craig C. Earle

10 October 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KFKathleen M. Fairfield
Kathleen M. Fairfield
KMKimberly Murray
Kimberly Murray
FLF. Lee Lucas
F. Lee Lucas
HWHeidi R. Wierman
Heidi R. Wierman
CECraig C. Earle
Craig C. Earle
JWJoan L. Warren
Joan L. Warren
Purpose: This analysis identifies factors associated with completion of adjuvant chemotherapy for patients with ovarian cancer and subsequent use of health services. Patients and Methods: We used the Surveillance, Epidemiology, and End Results (SEER) –Medicare database to identify 4,617 women age 65 years or older with ovarian cancer diagnosed from 2001 to 2005. By using multivariable analyses with completion of chemotherapy as the outcome of interest, we describe factors associated with completion of treatment, including age, race, marital status, comorbidities, and sociodemographic factors. Use of health services was captured from Medicare claims. Results: Among 4,617 patients with untreated ovarian cancer, 1,329 (28.8%) received no chemotherapy, 1,139 (24.7%) received a partial course of chemotherapy, and 2,149 (46.5%) completed chemotherapy. Women age 75 years or older were at greater risk of incomplete chemotherapy versus women age 65 to 74 years (odds ratio [OR], 1.64; 95% CI, 1.33 to 2.04). Having two or more comorbidities was also significantly associated with incomplete chemotherapy (OR, 1.83; 95% CI, 1.34 to 2.50). Among women who received either a partial or complete course of chemotherapy, we did not find an increase in use of health services (hospitalizations, emergency department visits, or physician visits) for the oldest women (age 80 years or older) compared with younger women. Conclusion: There is considerable room for improvement in helping older patients with ovarian cancer initiate and complete chemotherapy. The oldest women who completed chemotherapy in this study did not use health services more than younger women did. Treatment teams for older patients with ovarian cancer should include expertise in geriatric assessment, should carefully identify medical and psychosocial barriers to completing treatment, and should support patients throughout treatment.

24 June 2010 in Cancer
Verified
Journal Article
Open access
PDF file
KFKathleen M. Fairfield
Kathleen M. Fairfield
FLF. Lee Lucas
F. Lee Lucas
CECraig C. Earle
Craig C. Earle
LSLaurie Small
Laurie Small
ETEdward L. Trimble
Edward L. Trimble
JWJoan L. Warren
Joan L. Warren
BACKGROUND: Regional differences in health services can point to disparities in access to healthcare. The authors performed a population‐based cohort study to examine differences in ovarian cancer treatment and mortality according to geographic region.METHODS: The Surveillance, Epidemiology, and End Results (SEER)‐Medicare database was used to identify 4589 women aged ≥65 years with ovarian cancer diagnosed between 1998 and 2002 who had Medicare claims filed from 1998 to 2005. Hospital Referral Region (HRR) was assigned according to patient zip code. The authors calculated the proportion of women in each HRR who underwent cancer‐directed surgery. With HRR as the predictor of interest, mortality and the receipt of cancer‐directed surgery were described in multivariate analyses.RESULTS: Among 4589 women with ovarian cancer, 3286 underwent cancer‐directed surgery. The receipt of cancer‐directed surgery varied by HRR (range, 53%‐88%). Women were less likely to undergo cancer‐directed surgery if they were older, nonwhite, had higher stage disease, or had more comorbidities. For example, white women were more likely to undergo such surgery (odds ratio, 1.41; 95% confidence interval, 1.10‐1.82) compared with all nonwhite women. HRR was a significant predictor of cancer‐directed surgery (P = .01). A significant correlation was observed between HRR and all‐cause mortality (P = .02); however, after adjusting for cancer‐directed surgery, that correlation was no longer significant (P = .10).CONCLUSIONS: There was regional variation in mortality among Medicare recipients with ovarian cancer, and access to cancer‐directed surgery explained some of that variation. Improving access to high‐quality cancer surgery for ovarian cancer may improve outcomes, particularly for minorities and for older women. Cancer 2010. © 2010 American Cancer Society.

14 August 2009 in International Journal for Equity in Health
Verified
Journal Article
Open access
PDF file
PSPonnila S Samuel
Ponnila S Samuel
JPJane P Pringle
Jane P Pringle
NJNathaniel W James
Nathaniel W James
SFSusan J Fielding
Susan J Fielding
KFKathleen M Fairfield
Kathleen M Fairfield
Introduction: Minority women, particularly immigrants, have lower cancer screening rates than Caucasian women, but little else is known about cancer screening among immigrant women. Our objective was to assess breast, cervical, and colorectal cancer screening rates among immigrant women from Cambodia, Somalia, and Vietnam and explore screening barriers.Methods: We measured screening rates by systematic chart review (N = 100) and qualitatively explored screening barriers via face-to-face questionnaire (N = 15) of women aged 50–75 from Cambodia, Somalia, and Vietnam attending a general medicine clinic (Portland, Maine, USA).Results: Chart Review– Somali women were at higher risk of being unscreened for breast, cervical, and colorectal cancer compared with Cambodian and Vietnamese women. A longer period of US residency was associated with being screened for colorectal cancer. We observed a 7% (OR 1.07, 95% CI 1.01–1.13, p = 0.01) increase in the odds that a woman would undergo a fecal occult blood test for each additional year in the US, and a 39% increase in the odds of a woman being screened by colonoscopy or flexible sigmoidoscopy for every five years of additional US residence (OR 1.39, 95% CI 1.21–1.61, p = 0.02). We did not observe statistically significant relationships between odds of being screened by mammography, clinical breast exam or papanicolaou test according to years in the US.Questionnaire– We identified several barriers to breast, cervical, and colorectal cancer screening, including discomfort with exams conducted by male physicians.Discussion: Somali women were less likely to be screened for breast, cervical, and colorectal cancer than Cambodian and Vietnamese women in this population, and uptake of colorectal cancer screening is associated with years of residency in this country. Future efforts to improve equity in cancer screening among immigrants may require both provider and community education.

19 February 2004 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
KFKathleen M. Fairfield
Kathleen M. Fairfield
DHDavid J. Hunter
David J. Hunter
GCGraham A Colditz
Graham A Colditz
CFCharles S. Fuchs
Charles S. Fuchs
DCDaniel W. Cramer
Daniel W. Cramer
SHSusan E. Hankinson
Susan E. Hankinson
The milk sugar lactose is an hypothesized risk factor for epithelial ovarian cancer because of possible direct toxic effects of its metabolites on oocytes or by compensatory gonadotropin stimulation. Women are presently encouraged to consume dairy products as a source of calcium to prevent osteoporosis. The objective of our study was to prospectively assess lactose, milk and milk product consumption in relation to ovarian cancer risk among 80,326 participants in the Nurses' Health Study who had no history of cancer other than nonmelanoma skin cancer. Participants in the Nurses' Health Study reported on known and suspected ovarian cancer risk factors in questionnaires mailed biennially from 1976 to 1996. Food frequency questionnaires were included in the years 1980, 1984, 1986 and 1990. Newly reported ovarian cancer was documented by review of medical records. During 16 years of follow‐up (1980–1996), 301 cases of invasive epithelial ovarian cancer were confirmed. Pooled logistic regression was used to control for age, body mass index (kg/m2), caffeine intake, oral contraceptive use, smoking history, parity and tubal ligation. For all subtypes of invasive ovarian cancer combined, we observed a nonsignificant 40% greater risk for women in the highest category of lactose consumption compared to the lowest (multivariate relative risk (RR) 1.40, 95% confidence interval (CI), 0.98–2.01). We observed a 2‐fold higher risk of the serous ovarian cancer subtype among those in the highest category of lactose consumption compared to the lowest (RR 2.07, 95% CI, 1.27–3.40). For each 11‐gram increase in lactose consumption (the approximate amount in one glass of milk), we observed a 20% increase in risk of serous cancers (RR 1.20, 95% CI, 1.04–1.39). Skim and low‐fat milk were the largest contributors to dietary lactose. Women who consumed one or more servings of skim or low‐fat milk daily had a 32% higher risk of any ovarian cancer (RR 1.32, 95% CI, 0.97–1.82) and a 69% higher risk of serous ovarian cancer (RR 1.69, 95% CI, 1.12–2.56) compared to women consuming 3 or less servings monthly. Controlling for fat intake did not change our findings. Our findings provide some support for the hypothesis that lactose intake increases risk of epithelial ovarian cancer. However, the observed excess risk appeared limited to the serous subtype of ovarian cancer in our study.